Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

This study tests a new combination chemotherapy regimen (VA + HAAG) for adults newly diagnosed with intermediate or high-risk acute myeloid leukemia (AML) — a fast-growing blood cancer. **You may be eligible if...** - You are 18–65 years old - You were recently diagnosed with intermediate or high-risk AML (not a type called APL/M3) - You have never had chemotherapy or targeted therapy before - Your liver, kidney, and pancreas are functioning well enough (based on blood tests) - You are generally functional day-to-day (able to care for yourself) **You may NOT be eligible if...** - Your AML developed from a previous blood disorder called chronic myelogenous leukemia - You have another active cancer requiring treatment - You have a serious uncontrolled infection - You have significant heart problems (weak heart function) - You have HIV or active hepatitis B or C Talk to your doctor to see if this trial is right for you.